Q3 EPS Estimates for Replimune Group Decreased by Analyst

Replimune Group, Inc. (NASDAQ:REPL) – Research analysts at Leerink Partnrs lowered their Q3 2025 earnings per share (EPS) estimates for shares of Replimune Group in a note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst J. Chang now expects that the company will earn ($0.71) per share for the quarter, down from their previous forecast of ($0.64). The consensus estimate for Replimune Group’s current full-year earnings is ($3.05) per share. Leerink Partnrs also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.82) EPS and FY2026 earnings at ($2.25) EPS.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.07.

Several other research analysts have also recently commented on REPL. Roth Capital raised Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Roth Mkm initiated coverage on shares of Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a research note on Tuesday. Finally, JPMorgan Chase & Co. increased their price target on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $16.80.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $11.40 on Friday. The firm has a market capitalization of $779.99 million, a PE ratio of -3.74 and a beta of 1.19. The company has a current ratio of 10.11, a quick ratio of 13.46 and a debt-to-equity ratio of 0.18. Replimune Group has a 1-year low of $4.92 and a 1-year high of $12.97. The business’s 50 day moving average is $11.44 and its 200-day moving average is $9.50.

Hedge Funds Weigh In On Replimune Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC raised its stake in shares of Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after acquiring an additional 2,656,173 shares during the last quarter. Braidwell LP boosted its stake in Replimune Group by 203.0% in the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after purchasing an additional 2,057,460 shares in the last quarter. Baker BROS. Advisors LP grew its holdings in shares of Replimune Group by 10.0% during the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after purchasing an additional 1,000,000 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Replimune Group by 12.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock valued at $53,505,000 after buying an additional 699,679 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Replimune Group in the 1st quarter valued at about $1,088,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.